ERBB2 and gastric cancer: In patients with advanced, HER2+ GC or gastro-esophageal junction (GEJ) adenocarcinoma, the addition of trastuzumab (T) to standard cisplatin/fluoropyrimidine chemotherapy improved overall survival significantly [10].